The use of hyphenated LC–MS technique for characterisation of impurity profiles during drug development

Abstract

As part of an integrated quality concept for impurities during drug development, the multidimensional evaluation of impurity profiles by LC–MS coupling is presented using peptide drugs as an example. This quality concept can be regarded as an adaptation of the ICH-requirements to the special situation during the drug development process. The primary goal is to obtain qualitative molecular weight information for impurity peaks detected at the same UV wavelength as for the impurity test procedure. The approach is focused on the investigation, if the impurities in a clinical batch were also present in the toxicologically qualified batch(es). Depending on the relevance of individual impurities in further batches or as degradation products, the molecular weight can be used as a starting point for further characterization and identification. Often, eluents with volatile buffers required for MS result in different selectivities and/or inferior chromatographic separation and sensitivity compared with nonvolatile buffers (e.g. phosphates). In these cases, peak ‘tracking’ especially for small peaks can become critical. A procedure is presented for on-line coupling of LC methods with non-volatile eluents to mass spectrometry.